CXCL12 and neoplasm: In response to tissue damage and inflammation in TME, CAFs attract polymorphonuclear leukocytes by secreting CXCL12, which in the presence of tumor-derived CCL20, additionally upregulate PD-L1 expression in neutrophils consequently inhibiting antitumor activity of T cells [132,133].